AOD-9604 dosing research protocols — the disulphide structure, reconstitution, handling

“What is the AOD-9604 dose?” is one of the most-searched questions about the human-growth-hormone C-terminal fragment — and the honest answer starts by refusing the premise. There is no validated human dose of AOD-9604 for any purpose, because AOD-9604 is not an approved medicine in any major jurisdiction and has never been through the kind of dose-finding programme that would establish one. What does exist is a published research record describing the amounts those studies administered, and one structural detail that sets AOD-9604 apart from the small linear peptides: an internal disulphide bridge that handling and quality control have to protect. This spoke reports the figures descriptively, explains the disulphide nuance, shows the reconstitution math, and is explicit throughout that this is a research reference, not a protocol to follow.

Why there is no validated human dose

The first thing to settle, before any number appears, is what kind of object an “AOD-9604 dose” is. It is not an approved dosing instruction, because AOD-9604 is not an approved medicine anywhere in the major regulatory world — there is no regulator-reviewed label, no marketed strength, and no dose-ranging programme that ran to registration. The compound holds GRAS (Generally Recognized As Safe) status from a US ingredient-regulatory perspective, but that is a food-ingredient classification, not a medicinal-product approval; it does not establish a human dose and is not the same thing as approval by the FDA, EMA, or the UAE Ministry of Health. The figures that circulate on forums and vendor pages are extrapolations: they reproduce amounts that appeared in a handful of preclinical and company-sponsored reports and present them as though they were established protocols. They are not.

That distinction is the whole point of this article, so it is worth stating plainly: nothing below is a recommendation, and there is no validated human dose of AOD-9604 for any unapproved use. The public peer-reviewed human pharmacokinetic record for the molecule is thin — most of the dose figures that exist come from animal-model and in-vitro work rather than from controlled human dose-finding trials. Read every figure that follows as “what these papers administered”, never as “what to take”.

There is no validated human dose of AOD-9604. The numbers that circulate are research-reference figures — what specific studies administered to observe a lipid-metabolism effect — not a protocol for any person to follow.

The disulphide-structure nuance

Here is the structural detail that makes AOD-9604 handling different from a small linear peptide. AOD-9604 corresponds to residues 177-191 of human growth hormone, with a tyrosine residue appended at the N-terminus (added in the original research to facilitate radiolabelling), giving a 16-residue synthetic peptide of approximately 1,815 Da, supplied as the acetate salt. Critically, it is not a flat chain: it carries an internal disulphide bridge formed between its two cysteine residues, the same disulphide loop preserved from the C-terminal end of the parent hormone.

That single bond changes the engineering. A short linear tetrapeptide like the kind covered in our Epitalon dosing spoke has no folding to get wrong — it dissolves and that is the end of the matter. A disulphide-containing peptide is different: the bridge has to be formed correctly during synthesis and then kept intactthrough purification, lyophilisation, shipping, reconstitution, and storage. Harsh handling, mechanical shearing, or oxidation can break or scramble that bond, and a peptide whose disulphide bridge has opened is no longer the same molecule even though the amino-acid sequence on the label is unchanged. This is why the disulphide-linked structure is repeatedly noted as making AOD-9604 synthesis more demanding than an equivalent-length linear peptide — and why disulphide-bridge integrity belongs on the certificate of analysis, not just sequence and mass.

The internal disulphide bridge is the load-bearing detail: it makes AOD-9604 harder to synthesise correctly and easier to damage in handling, so QC has to confirm the bridge is intact — mass and sequence alone do not prove it.

What the studies used (descriptive)

The AOD-9604 dosing record is best read as a small set of preclinical research reports rather than a clinical guideline. Each figure below is described as what that study administered — the route and amount — and, where an outcome is mentioned, strictly as a lipid-metabolism endpoint, never anything else.

• An oral rodent administration at 500 µg/kg. Ng and colleagues (2000) characterised AOD-9604 as a synthetic lipolytic domain of human growth hormone and, in a rodent study, administered it by the oral route at 500 µg/kg, reporting that it acted on lipid metabolism without an adverse effect on insulin sensitivity [1]. This is described purely as the dose and route the study administered and the lipid-metabolism finding it reported — not a regimen anyone should reproduce, and not a human dose.
• Subcutaneous and infusion routes in other studies. Other preclinical work administered AOD-9604 by injection — subcutaneous administration and infusion preparations — rather than orally. Heffernan and colleagues (2001), studying the lipolytic action in animal models, reported a lipolysis magnitude comparable to that of intact human growth hormone and showed the action was not mediated through the β3-adrenergic receptor [3]. Again: described as the route and the lipid-metabolism finding, not as a dosing instruction.
• In-vitro metabolism and identity. Cox and colleagues (2014) characterised AOD-9604’s in-vitro metabolism, identifying six metabolites — including the stable fragment CRSVEGSCG — and noted the compound’s status as a WADA-prohibited substance [2]. This is identity-and-handling context rather than a dose: it documents how the molecule is broken down and confirms that the cysteine-containing core fragment is what persists, which is directly relevant to verifying material identity on a COA.

The through-line is the same one that runs through the whole AOD-9604 literature: the administration figures that exist were gathered in animal models and cell systems to studythe molecule’s lipid metabolism, not to establish a regimen for general use. They describe experiments. They do not describe a validated human dose, and presenting them as one would misrepresent what the papers actually say.

Reconstitution & the syringe math

Reconstitution mechanics, as a laboratory-handling procedure, are simple in principle — but the disulphide nuance raises the stakes on technique. Introduce bacteriostatic water — sterile water with ~0.9% benzyl alcohol as a preservative — slowly down the inside wall of the vial rather than aiming the stream at the powder cake, then swirl gently to dissolve. Never shake. Shaking shears the peptide, and for a disulphide-containing molecule like AOD-9604 that mechanical stress is exactly the kind of insult that can disrupt the bridge or denature the peptide — so the “swirl, do not shake” rule that applies to all peptides matters more here, not less. The general diluent and documentation framework lives in our how to reconstitute research peptidesguide. The math below shows how a chosen mass in milligrams maps onto syringe units — it is laboratory handling arithmetic, not a use instruction.

Storage & handling

Storage discipline matters for AOD-9604 partly because of that disulphide bridge. As a lyophilised powder it is most stable at -20°C, protected from light; once reconstituted, the solution is generally kept refrigerated at 2-8°C and is typically rated for around 28 daysat that temperature, used within the window stated on the vendor’s documentation. Bacteriostatic water’s benzyl alcohol preservative is what allows a reconstituted multi-use vial to remain usable across that window rather than being a single-use preparation. Keeping the material cold and dark is not just generic good practice here: oxidative conditions are precisely what threaten the disulphide bond, so cold, dark, low-agitation storage is part of protecting the molecule’s identity, not merely its potency.

The handling subtlety specific to this molecule is therefore a quality-control one. A research-grade material should arrive with a third-party RP-HPLC purity assay of ≥98% peak area, mass-spectrometry confirmation of the parent ion at roughly 1,816 Da [M+H]⁺, and explicit confirmation of disulphide-bridge integrity — because mass and sequence alone do not prove the bridge is intact, and a disrupted bridge changes the molecule even when the label does not. The in-vitro metabolism work that documents the persistent cysteine-containing fragment underlines why identity verification of the disulphide core is meaningful for this compound [2]. Without that documentation, the “dose” on the label is only as trustworthy as the correctly folded mass actually in the vial.

Cycles and “protocols” — convention vs evidence

The schedules that circulate — a run of consecutive days, a break, a repeat — are presented online as though they were established protocols. They are not derived from any published human dose-response work. They are convention: patterns that propagate through forums and vendor pages without the dose-finding rigour that would justify a specific schedule. The public human pharmacokinetic record is thin, so there is no controlled human dataset that any particular cycle length, frequency, or duration could be drawn from.

The honest distinction is between what the literature describes and what it validates. The published record describes AOD-9604 administered in animal models and cell systems — an oral 500 µg/kg rodent administration [1], injection-route lipolysis studies reporting a magnitude comparable to intact human growth hormone [3], and in-vitro metabolism characterisation [2]. None of that amounts to a controlled human trial that validates any particular cycle for general use. So a “cycle” is a convention to recognise when reading the literature — not a dose-response-derived protocol, and not a recommendation made here.

A circulating “AOD-9604 cycle” is convention, not evidence. No controlled human trial has validated a particular dose, route, frequency, or course length — the published figures describe experiments in animals and cells, not a protocol for people.

Related reading in the AOD-9604 cluster

For what AOD-9604 is and where its research record stands, start with the AOD-9604 parent synopsis. For the molecular biology of the lipid-metabolism pathway, see AOD-9604 mechanism research; for the regulatory and evidence picture, see AOD-9604 evidence and regulatory status. For general diluent and documentation handling, see how to reconstitute research peptides, and run any vial-size / concentration / draw-volume combination through the free reconstitution calculator. Supply: AOD-9604 5 mg research-consultation page.

Further reading

Peer-reviewed citations used inline:

• [1] Ng et al. — Hormone Research 2000. Metabolic characterisation of the synthetic lipolytic domain (AOD-9604) of human growth hormone; an oral rodent administration at 500 µg/kg acting on lipid metabolism, with no adverse effect on insulin sensitivity. PMID 11146367.
• [2] Cox et al. — Drug Test Anal 2014. In-vitro metabolism of AOD-9604; six metabolites identified including the stable fragment CRSVEGSCG; WADA-prohibited status (relevant to identity and handling). PMID 25208511.
• [3] Heffernan et al. — Endocrinology 2001. Lipolytic action of AOD-9604 in animal models, comparable in magnitude to intact human growth hormone and not mediated through the β3-adrenergic receptor. PMID 11713213.

Last reviewed 12 June 2026. AOD-9604 is not an approved medicine in any major jurisdiction; this article is research education and not medical advice, and nothing here describes a dose for any person to take. Wellness Labs supplies AOD-9604 as research-grade lyophilised powder for non-clinical investigation — research use only, not for human consumption. Editorial inbox: info@uaewellnesslab.com.